{
  "id": 276,
  "text": "able 1.6Stage-related survivalofcervical cancerusing FIGO staging at diagnosis,by country orregionand period <html><body><table><tr><td rowspan=\"2\">Country (territory or region)</td><td rowspan=\"2\">Data source</td><td rowspan=\"2\">Period of diagnosis</td><td colspan=\"5\">FIGO stage at diagnosis (%)</td><td rowspan=\"2\">Follow-up</td><td rowspan=\"2\">Reference</td></tr><tr><td>I</td><td>11</td><td>III</td><td>IV</td><td>Unknown</td></tr><tr><td> India (Mumbai)</td><td>Hospital</td><td>2010</td><td></td><td>62</td><td>45</td><td>4</td><td></td><td>5-yr disease-free survival (3-yr for</td><td>Chopra et al.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: able 1.6Stage-related survivalofcervical cancerusing FIGO staging at diagnosis,by country orregionand period <html><body><table><tr><td rowspan=\"2\">Country (territory or region)</td><td rowspan=\"2\">Data source</td><td rowspan=\"2\">Period of diagnosis</td><td colspan=\"5\">FIGO stage at diagnosis (%)</td><td rowspan=\"2\">Follow-up</td><td rowspan=\"2\">Reference</td></tr><tr><td>I</td><td>11</td><td>III<\n\n<question>: ",
  "ChatGPT_response_0": "根据各国或地区的研究，不同期间诊断时使用FIGO分期进行存活率分析显示出不同的变化趋势。以印度孟买地区为例，2010年的研究表明，在诊断时处于III期的患者存活率为62%，IV期为45%，未知期为4%。这种变化趋势反映出不同疾病分期对患者存活率的影响，以及不同时期诊断带来的不同结果。因此，在进行癌症治疗及预后评估时，FIGO分期在不同时间段的使用可以帮助医生更精准地了解患者的病情和预后。",
  "query": "在各国或地区研究中，不同期间诊断时使用FIGO分期存活率有何变化趋势呢？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在各国或地区研究中，不同期间诊断时使用FIGO分期存活率有何变化趋势呢？\n\n<reference text>: able 1.6Stage-related survivalofcervical cancerusing FIGO staging at diagnosis,by country orregionand period <html><body><table><tr><td rowspan=\"2\">Country (territory or region)</td><td rowspan=\"2\">Data source</td><td rowspan=\"2\">Period of diagnosis</td><td colspan=\"5\">FIGO stage at diagnosis (%)</td><td rowspan=\"2\">Follow-up</td><td rowspan=\"2\">Reference</td></tr><tr><td>I</td><td>11</td><td>III</td><td>IV</td><td>Unknown</td></tr><tr><td> India (Mumbai)</td><td>Hospital</td><td>2010</td><td></td><td>62</td><td>45</td><td>4</td><td></td><td>5-yr disease-free survival (3-yr for</td><td>Chopra \n\n<reply>: ",
  "response": "根据各国或地区的研究，不同期间诊断时使用FIGO分期进行存活率分析显示出不同的变化趋势。以印度孟买地区为例，2010年的研究表明，在诊断时处于III期的患者存活率为62%，IV期为45%，未知期为4%。这种变化趋势反映出不同疾病分期对患者存活率的影响，以及不同时期诊断带来的不同结果。因此，在进行癌症治疗及预后评估时，FIGO分期在不同时间段的使用可以帮助医生更精准地了解患者的病情和预后。"
}